GlassScriptPhysician profile
Gulshan Oberoi
NPI 1174801765
$7,840.41
in general payments reported to CMS, 2019-2025
46 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $394 · 2021: $906 · 2022: $1,212 · 2023: $943 · 2024: $1,659 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,121.14 | 2021-2025 | |
| Sk Life Science, INC. | $1,029.20 | 2020-2025 | |
| Ucb, INC. | $700.70 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Acadia Pharmaceuticals INC | $528.22 | 2021-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $455.42 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $312.44 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $293.99 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Pfizer INC. | $287.99 | 2019-2025 | |
| Eisai INC. | $270.29 | 2024-2025 | |
| Lundbeck LLC | $258.43 | 2021-2025 | Rexulti, Vyepti |
| Sunovion Pharmaceuticals INC. | $240.29 | 2019-2022 | |
| Argenx US, INC. | $201.94 | 2022-2025 | Vyvgart Hytrulo |
| Allergan, INC. | $193.15 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $171.54 | 2023-2024 | Aptiom |
| Novartis Pharmaceuticals Corporation | $147.60 | 2019-2024 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gulshan Oberoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.